GlassScriptPhysician profile
Kavina Patel
NPI 1205417599
$3,616.32
in general payments reported to CMS, 2019-2025
13 companies · $1,943 in 2025
The $1,943 reported for 2025 was more than what 93% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $111 · 2023: $464 · 2024: $1,098 · 2025: $1,943.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,506.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,505.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,579.82 | 2022-2025 | |
| Pfizer INC. | $317.08 | 2023-2025 | |
| Ucb, INC. | $268.42 | 2024-2025 | Bimzelx |
| Incyte Corporation | $260.08 | 2023-2024 | Opzelura |
| Genzyme Corporation | $194.26 | 2024-2025 | |
| Galderma Laboratories, L.P. | $150.00 | 2025 | Nemluvio |
| Janssen Scientific Affairs, LLC | $146.81 | 2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $125.81 | 2025 | |
| Dermavant Sciences, INC. | $124.98 | 2023 | Vtama |
| Regeneron Healthcare Solutions, INC. | $124.98 | 2025 | Dupixent |
| Janssen Biotech, INC. | $124.98 | 2024 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.00 | 2024 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $94.10 | 2025 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kavina Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.